Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2- dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 1, 2005, Pages 21-32

  Eiseman, Julie L ^a,b   Lan, Jing ^a,b   Lagattuta, Theodore F ^b   Hamburger, Deborah R ^b   Joseph, Erin ^b   Covey, Joseph M ^c   Egorin, Merrill J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Geldanamycin; Heat shock proteins; Pharmacodynamics; Pharmacokinetics

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 AMINO 17 DEMETHOXYGELDANAMYCIN; 17 DEMETHOXY 17 [[(2 DIMETHYLAMINO)ETHYL]AMINO]GELDANAMYCIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; NSC 707545; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG SOLUBILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BENZOQUINONES; BREAST NEOPLASMS; FEMALE; INFUSIONS, INTRAVENOUS; LACTAMS, MACROCYCLIC; MICE; MICE, SCID; QUINONES; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 11244337455     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0865-3     Document Type: Article

References (72)

1. Akaike A (1979) A bayesian extention of the minimal AIC procedures of autoregressive model fitting. Biometrika 66:237
2. An WG, Schnur RC, Neckers L, Blagosklonny MV (1997) Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 40:60
3. An WG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355
4. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L (2001) Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7:2076
5. Bamberger CM, Wald M, Bamberger AM, Schulte HM (1997) Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin. Mol Cell Endocrinol 131:233
6. Banerji U, Walton MI, Orr R, Kelland L, Judson IR, Workman P (2000) Development and validation of pharmacodynamic end points in tumor and normal tissue to assess the effect of the HSP90 molecular chaperone inhibitor 17-allylamino-17-demethoxy geldanamycin (17AAG). Proc Am Assoc Cancer Res 41:721a
7. Banerji U, O'Donnel A, Scurr M, Benson C, Stapleton S, Raynaud F, Clarke S, Tlurner A, Workman P, Judson I (2003) A pharmacokinetically (PK)-pharmacodynamically (PD) guided phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino, 17-demethoxydgeldanamycin (17AAG). Proc Am Soc Clin Oncol 22:199
8. Basso AD, Solit DB, Munster PN, Rosen N (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159
9. Blagosklonny MV (2002) Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16:455
10. Blagosklonny MV, Toretsky J, Bohen S, Neckers L (1996) Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 93:8379
11. Brunton VG, Steele G, Lewis AD, Workman P (1998) Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase. Cancer Chemother Pharmacol 41:417
12. Chen HS, Singh SS, Perdew GH (1997) The Ah receptor is a sensitive target of geldanamycin-induced protein turnover. Arch Biochem Biophys 348:190
13. Chen EX, Bies R, Ramanthan RK, Zuhowski EG, Trump DL, Egorin MJ (2002) Population pharmacokinetic (PK) analysis of 17-(allylamino)-17- demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 484:122a
14. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N (2001) A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 8:289
15. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Wallon M, Judson I, Workman P (2000) Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17- demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19:4125
16. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115
17. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH (1970) Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23:442
18. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385
19. Egorin MJ, Sentz DL, Zuhowski EG, Dobson JM, Schulte TW, Neckers LM, Eiseman JL (1999) PC3 human prostrate xenograft retention of, and oncoprotein modulation by, 17-allylaminogeldanamycin (17AAG) in vivo. Proc Am Assoc Cancer Res 40:517
20. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 micel. Cancer Chemother Pharmacol 47:291
21. Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL (2002) Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49:7
22. Erb-B2 in the xenografts following treatment. Cancer Res 5(Suppl):3837
23. Glaze ER, Smith AC, Johnson DW, McCormick DL, Brown AB, Levin BS, Krishnaraj R, Lyubimov A, Egorin MJ, Tomaszewski JE (2003) Dose range-finding toxicity studies of 17-DMAG. Proc Am Assoc Cancer Res 44:162
24. Goetz M, Toft J, Reid J, Sloan J, Atherton P, Adjei A, Croghan G, Weinshilboum R, Erlichman C, Ames M (2002) A phase I trial of 17-allyl-amino-geldanamycin (17-AAG) in patients with advanced cancer. Euro J Cancer 38:54
25. Goetz MP, Toft DO, Ames MM, Erlichman C (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Anal Oncol 14:1169
26. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843
27. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003
28. Jez JM, Chen JC, Rastelli G, Stroud RM, Santi DV (2003) Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem Biol 10:361
29. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407
30. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940
31. Kim S, Kang J, Hu W, Evers BM, Chung DH (2003) Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 103:352
32. Kim S, Kang J, Qiao J, Kamal A, Burrows FJ, Evers BM, Chung DH (2003) Heat shock protein 90 inhibitors reduce neuroblastoma growth in vivo. Proc Am Assoc Cancer Res 44:152
33. Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA (2003) Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 278:5292
34. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478
35. Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2:3
36. Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, King CR, Yang D, Lippman ME, Landolfi NF, Dadachova E, Brechbiel MW, Waldmann TA (2000) Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst 92:1573
37. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD (1994) Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res 54:2724
38. Munster PN, Basso A, Solit D, Norton L, Rosen N (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E.A. Sausville, Combining cytotoxics and 17-allylamino, 17- demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clin Cancer Res 7:2228
39. Munster PN, Basso A, Solit D, Norton L, Rosen N (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E.A. Sausville, Combining cytotoxics and 17-allylamino, 17- demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clin Cancer Res 7:2228
40. Munster PN, Basso A, Solit D, Norton L, Rosen N (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E.A. Sausville, Combining cytotoxics and 17-allylamino, 17- demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clin Cancer Res 7:2228
41. Munster PN, Marchion DC, Basso AD, Rosen N (2002) Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 62:3132
42. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61
43. Nimmanapalli R, Bhalla K (2002) Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene 21:8584
44. Nimmanapalli R, O'Bryan E, Bhalla K (2001) Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 61:1799
45. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN (2003) Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 102:269
46. Noker PE, Thompson RB, Smith AC, Tomaszewski JE, Page JG (1999) Toxicity and pharmacokinetics of 17-allylaminogeldanamycin (17-AAG, NSC-330507) in dogs. Proc Am Assoc Cancer Res 40:121
47. Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU (1998) In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143:901
48. Page JG, Noker PE, Tomaszewski JE, Smith AC (1999) Lack of schedule dependent toxicity of 17-allylaminogeldanamycin (17-AAG, NSC-330507) in rats. Proc Am Assoc Cancer Res 40:121
49. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1998) ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 17:4829
50. Piper PW (2001) The Hsp90 chaperone as a promising drug target. Curr Opin Investig Drugs 2:1606
51. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65
52. Rocci ML Jr, Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 16:203
53. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260
54. Sasaki K, Yasuda H, Onodera K (1979) Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives. J Antibiot (Tokyo) 32:849
55. Scheibel T, Buchner J (1998) The Hsp90 complex - a super-chaperone machine as a novel drug target. Biochem Pharmacol 56:675
56. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG (1995) Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38:3806
57. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273
58. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM (1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16:5839
59. Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR (2002) ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res 22:1993
60. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM (2002) 17-DMAG (NSC 07545), a water-soluble geldanamycin analog, has superior in vitro and in vivo antitumor activity compared to the hsp90 inhibitor 17-AAG. Eur J Cancer 38 [Suppl 7]:60
61. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM (2003) 17-DMA-geldanamycin is a novel water-soluble, orally bioavailable Hsp90 inhibitor with potent in vitro and in vivo anticancer activity. Proc Am Assoc Cancer Res 44:153
62. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986
63. Solit DB, Anana M, Valentin G, De La Cruz A, Tong W, Busam K, Reuter V, Kelly WK, Rosen N, Scher H (2003) Phase I trial of 17-AAG (17-allylamino-17- demethoxygeldanamycin) in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 22:198
64. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239
65. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305
66. Takimoto CH, Diggikar S (2002) Heat shock protein and proteasome targeting agents. Hematol Oncol Clin North Am 16:1269
67. Uehara Y, Hori M, Takeuchi T, Umezawa H (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 6:2198
68. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH (1998) The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18:1517
69. Wilson RH, Takimoto CH, Agnew EB, Morrison G, Grollman F, Thomas RR, Saif MW, Hopkins J, Allegra C, Grochow L, Szabo E, Hamilton JM, Monahan BP, Neckers L, Grem JL (2001) Phase I pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:82a
70. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276:3702
71. Yamaki H, Suzuki H, Choi EC, Tanaka N (1982) Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group. J Antibiot (Tokyo) 35:886
72. Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 6:79